13-Dec-2024
No headlines found.
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
PRNewswire (Tue, 12-Nov 4:58 PM ET)
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
PRNewswire (Wed, 6-Nov 4:03 PM ET)
PRNewswire (Sat, 2-Nov 11:00 AM ET)
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRNewswire (Wed, 30-Oct 4:30 PM ET)
PRNewswire (Mon, 14-Oct 10:56 AM ET)
Business Wire (Mon, 14-Oct 8:19 AM ET)
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
PRNewswire (Thu, 19-Sep 7:00 AM ET)
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Vanda Pharmaceuticals trades on the NASDAQ stock market under the symbol VNDA.
As of December 13, 2024, VNDA stock price declined to $4.61 with 450,616 million shares trading.
VNDA has a beta of 0.58, meaning it tends to be less sensitive to market movements. VNDA has a correlation of 0.01 to the broad based SPY ETF.
VNDA has a market cap of $268.72 million. This is considered a Small Cap stock.
Last quarter Vanda Pharmaceuticals reported $48 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.07.
In the last 3 years, VNDA traded as high as $18.00 and as low as $3.30.
The top ETF exchange traded funds that VNDA belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
VNDA has underperformed the market in the last year with a price return of +16.4% while the SPY ETF gained +29.9%. VNDA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.6% and -10.5%, respectively, while the SPY returned +7.8% and +0.3%, respectively.
VNDA support price is $4.49 and resistance is $4.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNDA shares will trade within this expected range on the day.